Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

June 14, 2017June 14, 2017

PETA Science Consortium Gives Vitrocell’s Animal-free Test Equipment to Labs in US and Europe

Idiopathic Pulmonary Fibrosis, News

PETA’s International Science Consortium (PISC) is donating $400,000 worth of Vitrocell animal-free inhalation test equipment to four institutions in the United States and Europe. PISC promotes non-animal research methods and coordinates the scientific ... Read more

May 23, 2017May 23, 2017

Adding Noninvasive Ventilator to At-home Oxygen Therapy Benefits COPD Patients

COPD, News

Adding a noninvasive ventilator to home oxygen therapy prolonged the time to hospital readmission for patients with chronic obstructive pulmonary disease (COPD) after an acute exacerbation. The study with the findings, ... Read more

May 22, 2017May 22, 2017

Galecto’s Inhaled IPF Therapy Candidate Shows Early Promise in Clinical Trial

Idiopathic Pulmonary Fibrosis, News

Inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients, Galecto Biotech reports. The results came from a Phase 1b/2a clinical trial (NCT02257177) evaluating TD139 in two parts. Phase 1b was ... Read more

May 10, 2017May 11, 2017

Pulmatrix Receives US Patent for PUR0200, an Inhaled Formulation for Lung Diseases

COPD, News

Pulmatrix has received a U.S. patent for PUR0200, an inhaled formulation of tiotropium bromide for lung diseases such as chronic obstructive pulmonary disease (COPD). The company said the powder it developed does a better ... Read more

April 26, 2017April 26, 2017

Registration Under Way for Pulmonary Fibrosis Foundation Summit

Idiopathic Pulmonary Fibrosis, News

Registration is under way for this fall’s Pulmonary Fibrosis Foundation Summit in Nashville, a key focus of which will be new research on the disease. Those interested in presenting their studies ... Read more

April 19, 2017April 19, 2017

FDA Agrees with ProMetic’s Protocol for PBI-4050 in IPF Clinical Trials

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences recently announced that the U.S. Food and Drug Administration (FDA) agreed with the design of the first Phase 2/3 clinical trials evaluating PBI-4050 for idiopathic pulmonary fibrosis (IPF) ... Read more

April 18, 2017April 19, 2017

Bristol-Myers, Nordic Partnering on Development of Biomarkers for Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Bristol-Myers Squibb and Nordic Bioscience have agreed to work together to develop biomarkers for diagnosing and monitoring patients with fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). IPF is a fatal, rare lung ... Read more

April 13, 2017April 13, 2017

NuMedii and Three Lakes Partners Collaborate to Discover New Therapies for IPF

Idiopathic Pulmonary Fibrosis, News

NuMedii and Three Lakes Partners are collaborating to discover and advance new therapies for idiopathic pulmonary fibrosis (IPF). Under the agreement, the companies will use NuMedii’s predictive big data intelligence technology, ... Read more

April 7, 2017April 7, 2017

Lung Institute Wants to Raise Awareness of COPD-Depression Link on World Health Day

COPD, News

The Lung Institute is trying to raise awareness of the link between chronic obstructive pulmonary disease (COPD) and depression in honor of World Health Day, whose focus this year is depression. ... Read more

March 31, 2017March 31, 2017

Chantix is Effective, Safe Therapy to Stop Smoking, Researchers Opine

Lung Cancer, News

Chantix (varenicline) is an effective and safe therapy to quit smoking, according to researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University. The therapy ultimately could have prevented heart attacks ... Read more